PL2861579T3 - Pochodne benzamidu do hamowania aktywności ABL 1, ABL 2 i BCR-ABL 1 - Google Patents
Pochodne benzamidu do hamowania aktywności ABL 1, ABL 2 i BCR-ABL 1Info
- Publication number
- PL2861579T3 PL2861579T3 PL13730652T PL13730652T PL2861579T3 PL 2861579 T3 PL2861579 T3 PL 2861579T3 PL 13730652 T PL13730652 T PL 13730652T PL 13730652 T PL13730652 T PL 13730652T PL 2861579 T3 PL2861579 T3 PL 2861579T3
- Authority
- PL
- Poland
- Prior art keywords
- abl1
- abl2
- bcr
- inhibiting
- activity
- Prior art date
Links
- 101100268645 Caenorhabditis elegans abl-1 gene Proteins 0.000 title 1
- 150000003936 benzamides Chemical class 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261647174P | 2012-05-15 | 2012-05-15 | |
| US201361790967P | 2013-03-15 | 2013-03-15 | |
| PCT/IB2013/053768 WO2013171639A1 (en) | 2012-05-15 | 2013-05-09 | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
| EP13730652.8A EP2861579B9 (en) | 2012-05-15 | 2013-05-09 | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2861579T3 true PL2861579T3 (pl) | 2018-07-31 |
Family
ID=48670630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13730652T PL2861579T3 (pl) | 2012-05-15 | 2013-05-09 | Pochodne benzamidu do hamowania aktywności ABL 1, ABL 2 i BCR-ABL 1 |
Country Status (50)
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3243826T1 (sl) | 2012-04-26 | 2020-03-31 | Bristol-Myers Squibb Company | Derivati imidazotiadiazola in imidazopirazina kot proteazno aktivirani receptor 4 (PAR4) inhibitorji za zdravljenje agregacije trombocitov |
| MX357305B (es) | 2012-05-15 | 2018-07-04 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1. |
| AU2013261127B2 (en) * | 2012-05-15 | 2015-03-12 | Novartis Ag | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
| AU2013261130A1 (en) * | 2012-05-15 | 2014-10-23 | Novartis Ag | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
| EA201492005A1 (ru) * | 2012-05-15 | 2015-04-30 | Новартис Аг | Бензамидные производные для ингибирования активности abl1, abl2 и bcr-abl1 |
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| EA035929B1 (ru) | 2013-01-15 | 2020-09-02 | Инсайт Холдингс Корпорейшн | ТИАЗОЛКАРБОКСАМИДЫ И ПИРИДИНКАРБОКСАМИДЫ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Pim-КИНАЗЫ |
| EA201690458A1 (ru) | 2013-08-23 | 2016-07-29 | Инсайт Корпорейшн | Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы |
| WO2015064764A1 (ja) * | 2013-11-01 | 2015-05-07 | 宇部興産株式会社 | アリーロイル（オキシ又はアミノ）ペンタフルオロスルファニルベンゼン化合物、薬学的に許容されるその塩、及びそのプロドラッグ |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| AU2015217221A1 (en) | 2014-02-13 | 2016-08-11 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
| UY36032A (es) | 2014-03-14 | 2015-10-30 | Novartis Ag | Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas |
| JP2017520545A (ja) | 2014-07-02 | 2017-07-27 | リガンド・ファーマシューティカルズ・インコーポレイテッド | プロドラッグ化合物およびそれらの使用 |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| MX389663B (es) | 2014-10-14 | 2025-03-20 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas. |
| US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
| CN104478911A (zh) * | 2014-12-19 | 2015-04-01 | 成都安斯利生物医药有限公司 | 一种制备3-三氟甲基吡咯硼酸的方法 |
| EP3789027A1 (en) * | 2015-01-13 | 2021-03-10 | Kyoto University | Bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib or bafetinib for preventing and/or treating amyotrophic lateral sclerosis |
| MY190404A (en) | 2015-03-10 | 2022-04-21 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| ES2878188T3 (es) | 2015-07-29 | 2021-11-18 | Novartis Ag | Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3 |
| US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| ES2908376T3 (es) | 2015-11-03 | 2022-04-28 | Janssen Biotech Inc | Anticuerpos que se unen específicamente a PD-1 y usos de los mismos |
| CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
| US9931342B2 (en) | 2016-02-02 | 2018-04-03 | Duke University | Compositions and methods for the treatment of cancer |
| JP2019515932A (ja) * | 2016-04-29 | 2019-06-13 | アスター バイオテック リミテッド ライアビリティ カンパニー | チロシンキナーゼｂｃｒ−ａｂｌ阻害剤としての新規複素環化合物 |
| US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| US20200017482A1 (en) * | 2016-09-27 | 2020-01-16 | Novartis Ag | Surfactant systems for crystallization of organic compounds |
| EP3532047A4 (en) * | 2016-10-26 | 2020-07-01 | The University Of Georgia Research Foundation, Inc | METHODS OF TREATING MYELID LEUKEMIA |
| CN110506036A (zh) * | 2017-03-15 | 2019-11-26 | 太阳制药先进研究有限公司 | 环丙烷羧酸(5-{5-[n′-(2-氯-6-甲基苯甲酰基)肼基羰基]-2-甲基-苯基乙炔基}-吡啶-2-基)酰胺的新型无定形分散体 |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| WO2018216705A1 (ja) * | 2017-05-23 | 2018-11-29 | 国立大学法人京都大学 | 神経変性疾患の予防及び／又は治療剤 |
| EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| JP2021509907A (ja) | 2018-01-09 | 2021-04-08 | リガンド・ファーマシューティカルズ・インコーポレイテッド | アセタール化合物およびその治療的使用 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| KR102618168B1 (ko) * | 2018-07-06 | 2023-12-27 | 일양약품주식회사 | 프리온 질환의 예방 또는 치료를 위한 약제학적 조성물 |
| SG11202102367TA (en) | 2018-09-18 | 2021-04-29 | Terns Inc | Compounds for treating certain leukemias |
| KR102119150B1 (ko) * | 2018-10-23 | 2020-06-04 | 한국원자력의학원 | N-1h-벤지미다졸-2-일-3-(1h-피롤-1-일) 벤자미드를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물 |
| US11407735B2 (en) * | 2019-05-16 | 2022-08-09 | Novartis Ag | Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide |
| US11236070B2 (en) | 2019-05-16 | 2022-02-01 | Novartis Ag | Chemical process |
| GB201913110D0 (en) * | 2019-09-11 | 2019-10-23 | Benevolentai Bio Ltd | New compounds and methods |
| WO2021053559A1 (en) | 2019-09-18 | 2021-03-25 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| WO2021143927A1 (zh) * | 2020-01-19 | 2021-07-22 | 正大天晴药业集团股份有限公司 | 作为bcr-abl抑制剂的化合物 |
| EP4096790B1 (en) | 2020-01-28 | 2025-10-15 | TAPI Czech Industries s.r.o. | Solid state forms of asciminib and processes for the preparation thereof |
| WO2021156360A1 (en) | 2020-02-05 | 2021-08-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki) |
| CN111321200A (zh) * | 2020-02-28 | 2020-06-23 | 广州安镝声生物医药科技有限公司 | 一种细胞外abl1激酶活性检测试剂盒及其应用 |
| CN115124551B (zh) * | 2021-03-24 | 2024-04-30 | 奥锐特药业(天津)有限公司 | 一种高纯度米哚妥林的制备方法 |
| WO2022206937A1 (zh) * | 2021-04-01 | 2022-10-06 | 苏州晶云药物科技股份有限公司 | 一种吡唑取代的烟酰胺类化合物的盐酸盐新晶型及其制备方法 |
| JP2024518426A (ja) | 2021-05-11 | 2024-05-01 | ノバルティス アーゲー | 投与レジメン |
| MX2023013650A (es) | 2021-05-28 | 2024-01-05 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Compuesto usado como inhibidor de bcr abl. |
| CN114149409B (zh) * | 2021-11-16 | 2024-03-22 | 中国药科大学 | 一种具有蛋白激酶抑制活性的（杂）芳基酰胺类化合物 |
| CN116135851B (zh) * | 2021-11-17 | 2025-09-23 | 武汉众诚康健生物医药科技有限公司 | 一种芳香胺化合物及其应用 |
| WO2023114759A2 (en) * | 2021-12-13 | 2023-06-22 | The Regents Of The University Of California | Abl inhibitors and uses thereof |
| CN115109048B (zh) * | 2022-08-10 | 2023-12-08 | 中国药科大学 | 一种(杂)芳基酰胺类化合物 |
| KR20250102064A (ko) | 2022-11-10 | 2025-07-04 | 신톤 비.브이. | 애시미닙 염산염의 결정형 |
| WO2024257116A1 (en) * | 2023-06-13 | 2024-12-19 | Natco Pharma Limited | Novel polymorphic forms of asciminib and its pharmaceutical salts thereof |
| WO2025146653A1 (en) * | 2024-01-04 | 2025-07-10 | Biophore India Pharmaceuticals Pvt. Ltd | Process for the preparation of n- [4(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxy pyrrolidin-l-yl]-5-(lh-pyrazol-3-yl) pyridine-3- carboxamide and pharmaceutically acceptable salts thereof |
| WO2025151311A1 (en) * | 2024-01-10 | 2025-07-17 | Board Of Regents, The University Of Texas System | Nicotinamide derivatives |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
| US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
| US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
| US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| DE2845997A1 (de) | 1978-10-23 | 1980-04-30 | Bayer Ag | Pflanzenwachstumsregulierende mittel, verfahren zu ihrer herstellung und ihre verwendung zur regulierung des pflanzenwachstums |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| EP0333791A1 (de) | 1987-09-23 | 1989-09-27 | Ciba-Geigy Ag | Heterocyclische verbindungen |
| US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
| IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
| EP0923583A1 (de) | 1996-08-30 | 1999-06-23 | Novartis AG | Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens |
| JP2002513445A (ja) | 1996-09-06 | 2002-05-08 | オブデュキャット、アクチボラグ | 導電材料内の構造の異方性エッチング方法 |
| DE59711647D1 (de) | 1996-11-18 | 2004-06-24 | Biotechnolog Forschung Gmbh | Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| JP2002504540A (ja) | 1998-02-25 | 2002-02-12 | スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ | エポチロンの合成、その中間体およびそのアナログ |
| ES2342240T3 (es) | 1998-08-11 | 2010-07-02 | Novartis Ag | Derivados de isoquinolina con actividad que inhibe la angiogenia. |
| AU768220B2 (en) | 1998-11-20 | 2003-12-04 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| US6794397B2 (en) | 2000-01-27 | 2004-09-21 | Cytovia, Inc. | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| WO2003039529A1 (en) | 2001-11-07 | 2003-05-15 | 4Sc A.G. | Selective antibacterial agents |
| WO2003055477A1 (en) | 2001-12-21 | 2003-07-10 | 7Tm Pharma A/S | Method for the treatment of mc receptor related disorders with a chelate and/or a chelator |
| GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| SI1569907T1 (sl) | 2002-12-13 | 2016-06-30 | Ym Biosciences Australia Pty Ltd | Na nikotinamidu osnovani kinazni inhibitorji |
| AR043633A1 (es) | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US20080167347A1 (en) | 2005-01-20 | 2008-07-10 | Shiongi & Co., Ltd. | Ctgf Expression Inhibitor |
| JP2008540487A (ja) | 2005-05-11 | 2008-11-20 | ノボ ノルディスク アクティーゼルスカブ | 肥満症の治療に有用な新規ハロアルキルスルホン置換化合物 |
| WO2007002441A1 (en) | 2005-06-24 | 2007-01-04 | Emory University | Methods of use for non-atp competitive tyrosine kinase inhibitors to treat pathogenic infection |
| SI1746097T1 (sl) | 2005-07-20 | 2010-05-31 | Aventis Pharma Sa | dihidropiridin kondenzirani heterocikli postopek za njihovo pripravo njihova uporaba in sestavki ki jih vsebujejo |
| BRPI0709749A2 (pt) * | 2006-04-05 | 2011-07-26 | Novartis Ag | combinaÇÕes de agentes terapÊuticos para tratamento de cÂncer |
| WO2008021725A2 (en) | 2006-08-11 | 2008-02-21 | Smithkline Beecham Corporation | Chemical compounds |
| CA2667010A1 (en) | 2006-10-20 | 2008-05-02 | Irm Llc | Compositions and methods for modulating c-kit and pdgfr receptors |
| US7939690B2 (en) * | 2006-11-15 | 2011-05-10 | High Point Pharmaceuticals, Llc | Haloalkylsulfone substituted compounds useful for treating obesity and diabetes |
| EP2111402B1 (en) * | 2007-01-05 | 2012-03-07 | Bristol-Myers Squibb Company | Aminopyrazole kinase inhibitors |
| WO2008112695A2 (en) | 2007-03-12 | 2008-09-18 | Irm Llc | Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment |
| WO2008124393A1 (en) | 2007-04-04 | 2008-10-16 | Irm Llc | Benzothiazole derivatives and their use as protein kinase inhibitors |
| WO2008144253A1 (en) | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| KR20100039429A (ko) | 2007-08-02 | 2010-04-15 | 에프. 호프만-라 로슈 아게 | Ｃｎｓ 질환의 치료를 위한 벤즈아미드 유도체의 용도 |
| MX2010002905A (es) | 2007-09-17 | 2010-07-05 | Abbott Lab | Derivados de uracilo o timina para tratar la hepatitis c. |
| BRPI0915205A2 (pt) | 2008-06-11 | 2017-03-21 | Dana Farber Cancer Inst Inc | compostos e composições úteis para o tratamento de malária |
| TW201018670A (en) | 2008-09-29 | 2010-05-16 | Boehringer Ingelheim Int | New chemical compounds |
| CN102548987B (zh) | 2009-07-14 | 2014-04-16 | 江苏迈度药物研发有限公司 | 作为激酶抑制剂的氟取代化合物及其使用方法 |
| JP2011057661A (ja) | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
| CA2780892C (en) | 2009-11-13 | 2017-02-14 | Genosco | Kinase inhibitors |
| JO3634B1 (ar) * | 2009-11-17 | 2020-08-27 | Novartis Ag | طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| JP5676650B2 (ja) | 2010-01-29 | 2015-02-25 | ハンミ・サイエンス・カンパニー・リミテッドＨａｎｍｉ Ｓｃｉｅｎｃｅ Ｃｏ．， Ｌｔｄ． | プロテインキナーゼ阻害活性を有するチエノ［３，２−ｄ］ピリミジン誘導体 |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| CN102276500A (zh) * | 2011-05-05 | 2011-12-14 | 西安交通大学 | 水杨酰胺类抗肿瘤化合物及其合成方法和用途 |
| WO2012166951A1 (en) | 2011-05-31 | 2012-12-06 | Receptos, Inc. | Novel glp-1 receptor stabilizers and modulators |
| MX357305B (es) * | 2012-05-15 | 2018-07-04 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1. |
| AU2013261127B2 (en) | 2012-05-15 | 2015-03-12 | Novartis Ag | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
| EA201492005A1 (ru) * | 2012-05-15 | 2015-04-30 | Новартис Аг | Бензамидные производные для ингибирования активности abl1, abl2 и bcr-abl1 |
| AU2013261130A1 (en) * | 2012-05-15 | 2014-10-23 | Novartis Ag | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
-
2013
- 2013-05-09 AU AU2013261127A patent/AU2013261127B2/en active Active
- 2013-05-09 PE PE2020000185A patent/PE20210667A1/es unknown
- 2013-05-09 PE PE2014002006A patent/PE20150669A1/es not_active Application Discontinuation
- 2013-05-09 MY MYPI2014703394A patent/MY169377A/en unknown
- 2013-05-09 PE PE2016001014A patent/PE20161416A1/es unknown
- 2013-05-09 KR KR1020147031773A patent/KR102091893B1/ko active Active
- 2013-05-09 SG SG11201407152XA patent/SG11201407152XA/en unknown
- 2013-05-09 GE GEAP201313621A patent/GEP201606532B/en unknown
- 2013-05-09 WO PCT/IB2013/053768 patent/WO2013171639A1/en not_active Ceased
- 2013-05-09 TR TR2018/07023T patent/TR201807023T4/tr unknown
- 2013-05-09 EA EA201491824A patent/EA024391B1/ru not_active IP Right Cessation
- 2013-05-09 ME MEP-2018-117A patent/ME03095B/me unknown
- 2013-05-09 CU CUP2014000131A patent/CU24265B1/es unknown
- 2013-05-09 LT LTEP13730652.8T patent/LT2861579T/lt unknown
- 2013-05-09 MA MA37519A patent/MA37519B1/fr unknown
- 2013-05-09 AP AP2014007992A patent/AP3613A/xx active
- 2013-05-09 RS RS20180497A patent/RS57177B1/sr unknown
- 2013-05-09 JP JP2015512169A patent/JP6078639B2/ja active Active
- 2013-05-09 BR BR112014026383-3A patent/BR112014026383B1/pt active IP Right Grant
- 2013-05-09 CA CA2868958A patent/CA2868958C/en active Active
- 2013-05-09 DK DK13730652.8T patent/DK2861579T5/da active
- 2013-05-09 ES ES13730652.8T patent/ES2670601T3/es active Active
- 2013-05-09 NZ NZ701626A patent/NZ701626A/en unknown
- 2013-05-09 CN CN201380025539.6A patent/CN104302638B/zh active Active
- 2013-05-09 SI SI201330997T patent/SI2861579T1/en unknown
- 2013-05-09 PT PT137306528T patent/PT2861579T/pt unknown
- 2013-05-09 HR HRP20180695TT patent/HRP20180695T1/hr unknown
- 2013-05-09 MX MX2014013374A patent/MX359014B/es active IP Right Grant
- 2013-05-09 HU HUE13730652A patent/HUE039138T2/hu unknown
- 2013-05-09 EP EP13730652.8A patent/EP2861579B9/en active Active
- 2013-05-09 PL PL13730652T patent/PL2861579T3/pl unknown
- 2013-05-13 US US13/892,769 patent/US8829195B2/en active Active
- 2013-05-15 AR ARP130101692A patent/AR091063A1/es active IP Right Grant
- 2013-05-15 JO JOP/2013/0150A patent/JO3453B1/ar active
- 2013-05-15 UY UY0001034811A patent/UY34811A/es active IP Right Grant
- 2013-05-15 TW TW102117263A patent/TWI560183B/zh active
- 2013-09-05 UA UAA201412051A patent/UA113208C2/uk unknown
-
2014
- 2014-07-31 US US14/448,363 patent/US20140343086A1/en not_active Abandoned
- 2014-09-29 ZA ZA2014/07065A patent/ZA201407065B/en unknown
- 2014-10-13 TN TN2014000427A patent/TN2014000427A1/fr unknown
- 2014-10-14 CL CL2014002757A patent/CL2014002757A1/es unknown
- 2014-11-06 IL IL235566A patent/IL235566A/en active IP Right Grant
- 2014-11-12 DO DO2014000256A patent/DOP2014000256A/es unknown
- 2014-11-13 PH PH12014502531A patent/PH12014502531B1/en unknown
- 2014-11-14 GT GT201400253A patent/GT201400253A/es unknown
- 2014-11-14 CO CO14252517A patent/CO7131380A2/es unknown
- 2014-11-14 CR CR20140519A patent/CR20140519A/es unknown
- 2014-11-14 SV SV2014004850A patent/SV2014004850A/es unknown
-
2018
- 2018-05-18 CY CY20181100518T patent/CY1120235T1/el unknown
-
2022
- 2022-10-20 FR FR22C1053C patent/FR22C1053I2/fr active Active
- 2022-10-25 NO NO2022043C patent/NO2022043I1/no unknown
- 2022-10-25 HU HUS2200046C patent/HUS2200046I1/hu unknown
- 2022-10-26 NL NL301201C patent/NL301201I2/nl unknown
- 2022-11-02 CY CY2022033C patent/CY2022033I1/el unknown
- 2022-11-10 LT LTPA2022523C patent/LTC2861579I2/lt unknown
- 2022-12-02 LU LU00287C patent/LUC00287I2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2022033I1 (el) | Παραγωγα βενζαμιδιου για την αναστολη της δραστικοτητας των abl1, abl2 και bcr-abl1 | |
| HUE039664T2 (hu) | N-Arilamidinnel szubsztituált trifluoretil-szulfid-származékok mint atka- és rovarirtószerek | |
| ZA201503457B (en) | Active compound combinations comprising carboxamide derivatives and a biological control agent | |
| PH12014500970A1 (en) | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | |
| IL233529A0 (en) | 1, 5-naphthyridine derivatives and malac inhibitors containing them | |
| IL235681A (en) | 5-amino [1, 4] thiazines as 1bace inhibitors | |
| SG10201800741QA (en) | BENZO-[d][1,2,3]TRIAZINE COMPOUNDS AND USE AS p70S6K INHIBITORS | |
| HUE050104T2 (hu) | 3,5N-trihidroxi-alkánamid és származékok: eljárás ennek elõállítására és ennek felhasználása | |
| EP2802328A4 (en) | TRYPTOLINE DERIVATIVES HAVING KINASE INHIBITING ACTIVITY AND USES THEREOF | |
| PH12014500542A1 (en) | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals | |
| IL231096A0 (en) | 2-converted thiazoles (chroman-6-yloxy) and their use as pharmaceutical preparations | |
| TH1401006797A (th) | อนุพันธ์เบนซาไมด์สำหรับการยับยั้งสภาพออกฤทธิ์ของ abl1, abl2 และ bcr-abl1 | |
| LT2908643T (lt) | Veikliojo junginio deriniai, apimantys karboksamido darinius ir biologinės kontrolės agentą | |
| PL395184A1 (pl) | Nowe pochodne benzimidazolu, sposób wytwarzania i zastosowanie pochodnych benzimidazolu |